Related Experiment Video
Updated: Jun 13, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The problems of clinical trials and registries in rare diseases
Maurizio Luisetti1, Ilaria Campo, Roberta Scabini
1Clinica di Malattie dell'Apparato Respiratorio, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Via Golgi 19, 27100 Pavia, Italy. m.luisetti@smatteo.pv.it
Abstract:
Clinical trials to evaluate patients affected by rare diseases are often hampered by the difficulty of recruiting a critical sample size. Registries for rare conditions are thus extremely powerful tools for overcoming recruitment problems. Here we present and discuss the international experience with alpha1-antitrypsin deficiency achieved by the Alpha One International Registry, and national experience obtained with a large series of patients with pulmonary alveolar proteinosis.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Preclinical Development: Overview
Drug Regulation
Hazard Ratio
For example, in a clinical trial evaluating a...
